A Phase 3 interventional study of Xyrem in Narcolepsy With Cataplexy, sponsored by Jazz Pharmaceuticals. Completed at 20 sites in 4 countries. Open to participants aged 7 Years to 17 Years. Per ClinicalTrials.gov, last updated 2019-04-30.
Sponsored by Jazz Pharmaceuticals · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 18 studies in Narcolepsy by Jazz Pharmaceuticals — 1 open to participants now, 1 under way, 1 of them phase 3. Narcolepsy · Jazz Pharmaceuticals.
Among the 18 studies in Narcolepsy by Jazz Pharmaceuticals, this one is the 9th largest by enrollment of the 15 interventional ones that give a count, is the only one that started in 2014, is one of 8 in phase 3, and was the 6th registered.
158 studies on the registry are indexed under Narcolepsy; 38 are open to participants now.
Browse Narcolepsy studies →1 of the 18 studies in Narcolepsy by Jazz Pharmaceuticals is open now, in 1 country. Recruiting first, the newest first:
Jazz Pharmaceuticals · Sites in United States
Ages 18–75
By country, each count listing its studies:
Of the 30 Narcolepsy studies recruiting now, 12 (40%) set no upper age limit and 16 (53%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.
This study: 7 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
18 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 1 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 106 is above the median of 78 across 114 interventional studies indexed under Narcolepsy.
Median enrollment 120 across the 15 interventional studies, 500 across the 3 observational. Of the 16 that completed or were terminated, 12 (75%) have results posted.
This tab as a report to print or save as PDF → With an account.
Jazz Pharmaceuticals is the lead sponsor of 173 studies on the registry; 18 are open to participants now.
Of its 42 completed or terminated interventional studies of FDA-regulated products, 32 (76%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 18 studies in Narcolepsy by Jazz Pharmaceuticals, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this trial is to assess the efficacy and safety of Xyrem in pediatrics subjects with narcolepsy that includes cataplexy.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
In addition to the above inclusion criteria, subjects participating in the PK evaluation must meet the following inclusion criteria:
-
Exclusion Criteria:
In addition to the above exclusion criteria, subjects participating in the PK evaluation must not demonstrate the following:
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Active Xyrem at a dose ≤9 g/night
Drug: Xyrem
Xyrem placebo at a volume and regimen equivalent to the stable dose of Xyrem.
Drug: Xyrem
Change in Weekly Number of Cataplexy Attacks
Double-blind comparison of the change in weekly number of cataplexy attacks from the last 2 weeks of the Stable Dose Period to the 2 weeks of the Double-blind Treatment Period.
Time frame: From the end of the Stable Dose Period to the end of the Double-blind Treatment Period (2 weeks)
Clinical Global Impression of Change (CGIc) for Cataplexy Severity
CGIc for cataplexy severity from the end of the Stable Dose Period to the end of the Double-blind Treatment Period. The CGIc is a 7-point scale ranging from "very much improved" to "very much worse." A score of 0 = no change, a score of 3 = very much improved, and a score of -3 = very much worse.
Time frame: From the end of the Stable Dose Period to the end of the Double-blind Treatment Period (2 weeks)
Change in the Epworth Sleepiness Scale (ESS) (CHAD) Score
Change in the ESS (CHAD) score from the end of the Stable Dose Period to the end of the Double-blind Treatment Period. The ESS is a self-administered questionnaire with 8 questions. It provides a measure of a person's general level of daytime sleepiness, or their average sleep propensity in daily life. In the ESS for children and adolescents (CHAD), certain activities were modified. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness.
Time frame: From the end of the Stable Dose Period to the end of the Double-blind Treatment Period (2 weeks)
CGIc for Narcolepsy Overall
CGIc for narcolepsy overall from the end of the Stable Dose Period to the end of the Double-blind Treatment Period. The CGIc is a 7-point scale ranging from "very much improved" to "very much worse." A score of 0 = no change, a score of 3 = very much improved, and a score of -3 = very much worse.
Time frame: From the end of the Stable Dose Period to the end of the Double-blind Treatment Period (2 weeks)
Change in Quality of Life (QoL; SF-10 Physical and Psychosocial Summary Score) From the End of the Stable Dose Period to the End of the Double-blind Treatment Period
The SF-10 Health Survey for Children is a parent-completed survey that contains 10 questions adapted from the Child Health Questionnaire. The SF-10 is intended to produce physical and psychosocial health summary measures. Each of the 10 questions responses is scored with a point value from 1 to 6 (1 is the worst possible condition and 6 is the best possible condition). The SF-10 physical and psychosocial measures are scored such that higher scores indicate more favorable functioning. The questions and associated point values are separated into the Physical Health (PHS-10 domain) and Psychosocial Health (PSS-10 domain). The sums of the scores in each domain are standardized using the mean and standard deviation from a normal population (2006 sample). The standardized scores are transformed to norm based scoring (NBS) metric. Through NBS, scale scores are standardized to a mean of 50 and SD of 10 in the combined U.S. general population and clinical samples. NBS scores are reported
Time frame: From the end of the Stable Dose Period to the end of the Double-blind Treatment Period (2 weeks)
106 subjects were enrolled. Xyrem-naïve subjects (n=74) entered the Dose Titration Period (3 to 10 weeks). Xyrem-naïve and on Xyrem subjects (n= 99) entered the Stable Dose Period (2 to 3 weeks). 96 subjects then entered the Double-Blind Randomized Withdrawal Period (2 weeks). 95 subjects then entered the Open-label Safety Period (38 to 47 weeks).
| Milestone | Randomized to Xyrem | Randomized to Xyrem Placebo | Open-label Xyrem |
|---|---|---|---|
| Started | 31 | 32 | 43 |
| Completed | 30 | 32 | 33 |
| Not completed | 1 | 0 | 10 |
Double-blind comparison of the change in weekly number of cataplexy attacks from the last 2 weeks of the Stable Dose Period to the 2 weeks of the Double-blind Treatment Period.
| number of attacks | Xyrem | Xyrem Placebo |
|---|---|---|
| Change in Weekly Number of Cataplexy Attacks | 0.27 (-1.00 to 2.50) | 12.71 (3.44 to 19.77) |
CGIc for cataplexy severity from the end of the Stable Dose Period to the end of the Double-blind Treatment Period. The CGIc is a 7-point scale ranging from "very much improved" to "very much worse." A score of 0 = no change, a score of 3 = very much improved, and a score of -3 = very much worse.
| score on a scale | Xyrem | Xyrem Placebo |
|---|---|---|
| Clinical Global Impression of Change (CGIc) for Cataplexy Severity | -0.4 ± 1.12 | -1.5 ± 1.19 |
Change in the ESS (CHAD) score from the end of the Stable Dose Period to the end of the Double-blind Treatment Period. The ESS is a self-administered questionnaire with 8 questions. It provides a measure of a person's general level of daytime sleepiness, or their average sleep propensity in daily life. In the ESS for children and adolescents (CHAD), certain activities were modified. Each activity is scored on a scale ranging from 0-3, with 0 = would never fall asleep, and 3 = high chance of falling asleep. The total score ranges from 0-24, with a higher number representing an increased propensity for sleepiness.
| score on a scale | Xyrem | Xyrem Placebo |
|---|---|---|
| Change in the Epworth Sleepiness Scale (ESS) (CHAD) Score | 0.0 (-1.0 to 2.0) | 3.0 (1.0 to 5.0) |
CGIc for narcolepsy overall from the end of the Stable Dose Period to the end of the Double-blind Treatment Period. The CGIc is a 7-point scale ranging from "very much improved" to "very much worse." A score of 0 = no change, a score of 3 = very much improved, and a score of -3 = very much worse.
| score on a scale | Xyrem | Xyrem Placebo |
|---|---|---|
| CGIc for Narcolepsy Overall | -0.4 ± 0.95 | -1.4 ± 1.13 |
The SF-10 Health Survey for Children is a parent-completed survey that contains 10 questions adapted from the Child Health Questionnaire. The SF-10 is intended to produce physical and psychosocial health summary measures. Each of the 10 questions responses is scored with a point value from 1 to 6 (1 is the worst possible condition and 6 is the best possible condition). The SF-10 physical and psychosocial measures are scored such that higher scores indicate more favorable functioning. The questions and associated point values are separated into the Physical Health (PHS-10 domain) and Psychosocial Health (PSS-10 domain). The sums of the scores in each domain are standardized using the mean and standard deviation from a normal population (2006 sample). The standardized scores are transformed to norm based scoring (NBS) metric. Through NBS, scale scores are standardized to a mean of 50 and SD of 10 in the combined U.S. general population and clinical samples. NBS scores are reported
| score on a scale | Xyrem | Xyrem Placebo |
|---|---|---|
| SF-10 Physical Summary Score | 0 (-2.730 to 2.500) | 0 (-8.420 to 2.730) |
| SF-10 Psychosocial Summary Score | 0 (-6.240 to 2.680) | -2.670 (-8.020 to 2.670) |
Collected over Safety data are provided through the 120 day update.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Safety Population | 0/104 (0%) | 2/104 (1.9%) | 80/104 (76.9%) |
| Randomized Placebo | 0/32 (0%) | 0/32 (0%) | 10/32 (31.3%) |
| Event | Safety Population | Randomized Placebo |
|---|---|---|
| Acute PsychosisPsychiatric disorders | 1/104 | 0/32 |
| Suicidal IdeationPsychiatric disorders | 1/104 | 0/32 |
| Event | Safety Population | Randomized Placebo |
|---|---|---|
| SomnolenceNervous system disorders | 2/104 | 7/32 |
| EnuresisRenal and urinary disorders | 20/104 | 1/32 |
| NauseaGastrointestinal disorders | 20/104 | 0/32 |
| CataplexyNervous system disorders | 2/104 | 6/32 |
| VomitingGastrointestinal disorders | 19/104 | 0/32 |
| HeadacheNervous system disorders | 18/104 | 0/32 |
| Weight decreasedInvestigations | 12/104 | 1/32 |
| Decreased appetiteMetabolism and nutrition disorders | 9/104 | 0/32 |
| NasopharyngitisInfections and infestations | 9/104 | 0/32 |
| Upper respiratory tract infectionInfections and infestations | 9/104 | 0/32 |
106 subjects were enrolled. 63 subjects were randomized during the Double-blind Treatment Period. 106 subjects comprised the Enrolled population, and 63 subjects comprised the Efficacy population.
| Age, Categorical(Participants) | Enrolled Population | Placebo (Efficacy Population) | Xyrem (Efficacy Population) | Total |
|---|---|---|---|---|
| Enrolled Population — <=18 years | 106 | — | — | 106 |
| Enrolled Population — Between 18 and 65 years | 0 | — | — | 0 |
| Enrolled Population — >=65 years | 0 | — | — | 0 |
| Efficacy Population — <=18 years | — | 32 | 31 | 63 |
| Efficacy Population — Between 18 and 65 years | — | 0 | 0 | 0 |
| Efficacy Population — >=65 years | — | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Enrolled Population | Placebo (Efficacy Population) | Xyrem (Efficacy Population) | Total |
|---|---|---|---|---|
| Enrolled Population — Female | 43 | 0 | — | 43 |
| Enrolled Population — Male | 63 | 0 | — | 63 |
| Efficacy Population — Female | — | 15 | 13 | 28 |
| Efficacy Population — Male | — | 17 | 18 | 35 |
| Ethnicity (NIH/OMB)(Participants) | Enrolled Population | Placebo (Efficacy Population) | Xyrem (Efficacy Population) | Total |
|---|---|---|---|---|
| Enrolled Population — Hispanic or Latino | 6 | — | — | 6 |
| Enrolled Population — Not Hispanic or Latino | 100 | — | — | 100 |
| Enrolled Population — Unknown or Not Reported | 0 | — | — | 0 |
| Efficacy Population — Hispanic or Latino | — | 2 | 0 | 2 |
| Efficacy Population — Not Hispanic or Latino | — | 30 | 31 | 61 |
| Efficacy Population — Unknown or Not Reported | — | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Enrolled Population | Placebo (Efficacy Population) | Xyrem (Efficacy Population) | Total |
|---|---|---|---|---|
| Netherlands | 8 | 0 | 0 | 8 |
| United States | 62 | — | — | 62 |
| Italy | 25 | — | — | 25 |
| France | 10 | — | — | 10 |
| Finland | 1 | — | — | 1 |
| Region of Enrollment(participants) | Enrolled Population | Placebo (Efficacy Population) | Xyrem (Efficacy Population) | Total |
|---|---|---|---|---|
| Netherlands | — | 3 | 2 | 5 |
| United States | — | 17 | 16 | 33 |
| Italy | — | 9 | 9 | 18 |
| France | — | 3 | 4 | 7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Oct 2014 to primary completion in Feb 2017, 28 months.
Results were first posted in Apr 2019, 2 years 2 months after primary completion. A results delay was requested in Jan 2018.
Of 14 phase 3 interventional studies under Narcolepsy, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 40. This study's 28 months is close to that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Sodium Oxybate